APA (7th ed.) Citation

Ouchi, K., Takahashi, S., Sasaki, K., Yoshida, Y., Taniguchi, S., Kasahara, Y., . . . Ishioka, C. (2024). Genome-wide DNA methylation status is a predictor of the efficacy of anti-EGFR antibodies in the second-line treatment of metastatic colorectal cancer. International Journal of Colorectal Disease: Clinical and Molecular Gastroenterology and Surgery, 39(1), . https://doi.org/10.1007/s00384-024-04659-y

Chicago Style (17th ed.) Citation

Ouchi, Kota, et al. "Genome-wide DNA Methylation Status Is a Predictor of the Efficacy of Anti-EGFR Antibodies in the Second-line Treatment of Metastatic Colorectal Cancer." International Journal of Colorectal Disease: Clinical and Molecular Gastroenterology and Surgery 39, no. 1 (2024). https://doi.org/10.1007/s00384-024-04659-y.

MLA (9th ed.) Citation

Ouchi, Kota, et al. "Genome-wide DNA Methylation Status Is a Predictor of the Efficacy of Anti-EGFR Antibodies in the Second-line Treatment of Metastatic Colorectal Cancer." International Journal of Colorectal Disease: Clinical and Molecular Gastroenterology and Surgery, vol. 39, no. 1, 2024, https://doi.org/10.1007/s00384-024-04659-y.